Coronary artery disease is the build-up of plaque, or narrowing or blockage of the coronary arteries, primarily due to atherosclerosis. Cholesterol or fatty acid gets deposited on the inner walls of the major blood vessels, which supply blood, oxygen, and nutrients to the heart, and damages them. The decreased blood flow leads to angina, shortness of breath, and other related symptoms, such as neck or jaw pain and sweating.
Statistically, coronary artery disease-based mortality has decreased in developed markets. It is still responsible, however, for one-third of all deaths in individuals above the age of 35, according to a 2016 publication in Annals of Translational Medicine. Presently, there are several biopharmaceutical companies expanding their pipeline to develop monoclonal antibodies, vaccines, and personalized medicine, to inhibit cholesterol production.
This report by Mordor Intelligence provides extensive insights into the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases, and the status of clinical trials, across major regions of the world, are given, with data obtained from multiple sources. The report also comprises a list of key sponsors with pipeline products for the concerned market.
The report will cover analysis on trails and information on key sponsors, companies and researchers.
Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and our in-house team of research experts. The pipeline assessment reports are generated based on information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research is validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports is continuously updated to incorporate the most relevant and authentic information to our clients.
2. Research Methodology
3. Disease Epidemiology and Trends
4. Healthcare Expenditure and R&D Trends
5. Executive Summary
6. Clinical Trials Segmentation by Phase
6.1 Phase-III Product Candidates
6.2 Phase-II Product Candidates
6.3 Phase-I Product Candidates
7. Clinical Trials, Segmentation by Status
8. Pipeline Therapeutic Assessment (Infographic Charts and a Brief Description)
8.1. By Clinical Phase and Molecule Type
8.2. By Clinical Phase and Route of Administration
8.3 By Sponsor/Collaborator/Institutions
8.4 By Geography
9. Market Updates
10. Key Sponsor Profiles
11. Sources and Disclaimer
12. About Mordor Intelligence